Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin dose comparison during plasma exchange for inflammatory neurological disorders
IRCT20191115045446N2Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Jun 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of albumin (human) in neuroinflammatory conditions (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Colloid osmotic pressure and Edema level. Started Jun 2025; status: completed.
02
Drugs
albumin (human)
03
Conditions
neuroinflammatory conditions
Beyond the preview
Go deeper on IRCT20191115045446N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20191115045446N2.